title: Cryopreserved mobilized autologous blood progenitors stored for more than 2 years successfully support blood count recovery after high-dose chemotherapy.
abstract: OBJECTIVE
  The ability of hematopoietic progenitor cells-apheresis (HPC-A) that have been stored for many years after cryopreservation to reconstitute hematopoiesis following high-dose chemo/radiotherapy has not been well-documented.
  
  
  METHODS
  In this retrospective study, eight Canadian centers contributed data from 53 autologous stem cell transplants (ASCT) performed using HPC-A that had undergone long-term storage (>2 years, range 2-7 years) and 120 ASCT using HPC-A stored for <6 months (short-term storage).
  
  
  RESULTS
  The doses of nucleated and CD34(+) cells per kilogram recipient weight were similar between the short- (mean ± SD, 4.7 ± 4.9 × 10(8) and 6.8 ± 4.3 × 10(6), respectively) and long- (4.0 ± 4.9 × 10(8) and 6.1 ± 3.4 × 10(6), respectively) term storage groups. The median days to neutrophils (absolute neutrophil count; ANC) >0.5 × 10(9)/L (median 11 days for both short- and long-term storage) and platelets >20 × 10(9)/L (median 12 and 11 for short- and long-term storage, respectively) post-ASCT were not significantly different between the two groups. When ASCT performed with <5 × 10(6)/kg CD34(+) cells was compared there was also no difference in ANC or platelet recovery (median 12 days for both after short-term storage, and 12 and 11 days, respectively, after long-term storage). Fourteen HPC-A products stored for >5 years also showed similar count recoveries as the entire long-term storage group (median 11 days for both ANC and platelets).
  
  
  CONCLUSIONS
  Cryopreserved HPC-A can be stored for at least 5 years with no apparent loss in their ability to support hematopoietic reconstitution after high-dose chemotherapy.
authors.affiliation: The Clinical Cell Therapy Laboratory of the BC Cancer Agency, Vancouver, Canada.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Cameron
authors.forename: Adisak
authors.initials: A
authors.lastname: Tantiworawit
authors.forename: Mike
authors.initials: M
authors.lastname: Halpenny
authors.forename: Brenda
authors.initials: B
authors.lastname: Letcher
authors.forename: Sue
authors.initials: S
authors.lastname: Berrigan
authors.forename: Karen
authors.initials: K
authors.lastname: Hindmarsh
authors.forename: Angeline
authors.initials: A
authors.lastname: Giftakis
authors.forename: Johanne
authors.initials: J
authors.lastname: Fortier
authors.forename: Pamela
authors.initials: P
authors.lastname: O'Hoski
authors.forename: Donna
authors.initials: D
authors.lastname: Hogge
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D015925:Cryopreservation; D005260:Female; D006410:Hematopoiesis / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D009504:Neutrophils / Q000276:immunology; D012189:Retrospective Studies; D013997:Time Factors; D014182:Transplantation, Autologous; D055815:Young Adult
chemical_list: D018952:Antigens, CD34; D000970:Antineoplastic Agents